Strategies to target cancers with ARID1A and KDM6A deficiency are not as mature as those targeting the PI3K/AKT/mTOR pathway [99,140]; however, several recent promising results have been reported [97,141,142,143], offering hope for future research. Here, ARID1A is linked to cancer.